A detailed history of Core Cap Advisors, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Core Cap Advisors, LLC holds 479 shares of VRNA stock, worth $21,574. This represents 0.0% of its overall portfolio holdings.

Number of Shares
479
Holding current value
$21,574
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$15.46 - $30.16 $7,405 - $14,446
479 New
479 $13,000
Q1 2024

Aug 08, 2024

BUY
$15.3 - $20.24 $10,052 - $13,297
657 New
657 $10,000
Q4 2022

Feb 10, 2023

BUY
$9.84 - $26.13 $5,904 - $15,678
600 New
600 $15,000
Q2 2022

Aug 11, 2022

BUY
$3.55 - $5.06 $2,130 - $3,035
600 New
600 $3,000
Q1 2022

Apr 29, 2022

SELL
$4.82 - $6.98 $2,892 - $4,188
-600 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$3.91 - $7.08 $2,346 - $4,248
600 New
600 $4,000

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.75B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Core Cap Advisors, LLC Portfolio

Follow Core Cap Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Cap Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Core Cap Advisors, LLC with notifications on news.